Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex has a portfolio of investigational medicines, two of which are in late stages of clinical development. Cordex's ATPace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 clinical trial for the treatment of heart failure in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding CDP-1050 as a paradigm for the treatment of heart failure, satisfaction of the medical community and regulatory authorities as to the
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... -- Brooklyn residents now have a new place to go ... Nunzio Saulle , M.D., a board-certified physiatrist, is ... Physical Medicine and Rehabilitation (PM&R) practice in ... Health Plus Management, LLC is managing the day-to-day operations ... Avenue. This new PM&R practice will treat patients suffering ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of Jain PharmaBiotech,s new report "Biomarkers ... offering. This report follows the ... that can be objectively measured and evaluated as ... as well as pharmacological responses to a therapeutic ...
(Date:3/4/2015)... 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) (the "Company") ... collaborative research program with Emerald Logic, a ... Evolution Technology (FACET), Emerald Logic analyzed Resverlogix,s ... from each of 798 patients who participated ... ASSERT, SUSTAIN and ASSURE. The objective of ...
(Date:3/4/2015)... Proove Biosciences , a ... excited to announce the launch of their CME-accredited ... Management of Pain”. , The continuing medical education ... next year. The focus of the program is ... pain treatments, integrate appropriate pain management techniques, and ...
Breaking Biology Technology:NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3
... BERKELEY, Calif., March 28 Aerovance Inc. today,announced ... financing. Oxford,Finance Corporation led the syndicate, which includes ... $10 million from the financing line,at closing. The ... of,corporate milestones., "This financing reflects continued interest ...
... Joins Investor Syndicate, VIENNA, Austria, March ... novel antibodies and antibody fragments,based on its ... it,has acquired future royalty obligations to New ... Modular Antibody Technology was originally developed by ...
... HAMBURG, Germany and OXFORD, England, March 28 /PRNewswire-FirstCall/,-- ... financial,results according to IFRS for the year ended ... year were driven by strong progress in the,Company,s ... of Neuro3d, the sale of Evotec Technologies (ET), ...
Cached Biology Technology:Antibody Engineering Company F-Star Buys Back Royalty Obligations 2Evotec Announces Financial Results for 2007 2Evotec Announces Financial Results for 2007 3Evotec Announces Financial Results for 2007 4Evotec Announces Financial Results for 2007 5Evotec Announces Financial Results for 2007 6Evotec Announces Financial Results for 2007 7Evotec Announces Financial Results for 2007 8
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
(Date:1/22/2015)... Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of ... of its new website design. "When we launched ... says Peter O,Neill , founder and CEO of FindBiometrics. ... needs involvement from the key players on a very broad ...
(Date:1/22/2015)... Hall E -   EyeLock Inc. , a market leader ... its EyeLock ID technology integrated in a 3D printed automobile ... Ridge National Laboratory (ORNL) at the 2015 North ... is being used to validate the driver and authorize the ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... In the first field trial of plants genetically tweaked ... plants handily beat out their wild-type counterparts. The results ... alternative for cleaning up polluted soil. , The new ... Science and Technology, show that three transgenic lines of ...
... Hotspots Revisited identifies 34 regions worldwide where 75 percent ... survive within habitat covering just 2.3 percent of the ... the five largest U.S. states). This habitat originally covered ... in size to Russia and Australia combined. The new ...
... novel bio-bar-code amplification (BCA) technology, researchers analyzing fluid from ... protein linked in recent studies to Alzheimer's disease. , ... : , - Gold nanoparticles and bio-bar codes ... Codes for the Ultrasensitive Detection of Proteins ,- ...
Cached Biology News:Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 2Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 3Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 4Biodiversity hotspots identify conservation priorities 2Biodiversity hotspots identify conservation priorities 3Biodiversity hotspots identify conservation priorities 4Biodiversity hotspots identify conservation priorities 5Nanoscale Diagnostic Sets Sights on Alzheimer's 2Nanoscale Diagnostic Sets Sights on Alzheimer's 3
... is a high-quality four-place microplate shaker with ... speed is adjustable from 100 to 1350 ... a small orbit ensure effective shaking for ... quick and easy to set for 0 ...
... Ascent FL is equipped ... luminometric measurement technologies that ... of advanced features of ... Ascent. Fluoroskan Ascent FL ...
Rabbit polyclonal to STUB1 ( Abpromise for all tested applications). entrezGeneID: 10273 SwissProtID: Q9UNE7...
... stainless steel rack holders ... mechanism that permits selection ... angles, and "snap-in" product ... rack holder will accomodate ...
Biology Products: